作者
Li Zhang, Yan Huang, Shaodong Hong, Yunpeng Yang, Gengsheng Yu, Jun Jia, Peijian Peng, Xuan Wu, Qing Lin, Xuping Xi, Jiewen Peng, Mingjun Xu, Dongping Chen, Xiaojun Lu, Rensheng Wang, Xiaolong Cao, Xiaozhong Chen, Zhixiong Lin, Jianping Xiong, Qin Lin, Conghua Xie, Zhihua Li, Jianji Pan, Jingao Li, Shixiu Wu, Yingni Lian, Quanlie Yang, Chong Zhao
发表日期
2016/10/15
期刊
The Lancet
卷号
388
期号
10054
页码范围
1883-1892
出版商
Elsevier
简介
Background
Outcomes are poor for patients with recurrent or metastatic nasopharyngeal carcinoma and no well established first-line chemotherapy is available for the disease. We compared the efficacy and safety of gemcitabine plus cisplatin versus fluorouracil plus cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.
Methods
In this multicentre, randomised, open-label, phase 3 trial, patients with recurrent or metastatic nasopharyngeal carcinoma were recruited from 22 hospitals in China. Key inclusion criteria were Eastern Cooperative Oncology Group performance status of 0 or 1, adequate organ function, and measurable lesions according to Response Evaluation Criteria in Solid Tumors version 1.1. Patients were randomly assigned in a 1:1 ratio to receive either gemcitabine (1 g/m2 intravenously on days 1 and 8) and cisplatin (80 mg/m2 intravenously on day 1), or fluorouracil (4 g/m2 in …
学术搜索中的文章
L Zhang, Y Huang, S Hong, Y Yang, G Yu, J Jia… - The Lancet, 2016
